Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other cardiovascular agent, wherein the at least one other cardiovascular agent is an angiotesin II receptor antagonist.